Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Actos)
6,564 results
  • Supplemental Pioglitazone to Patients of CML with Suboptimal TKI Response: A Pragmatic Pilot Study. [Journal Article]
    Indian J Hematol Blood Transfus. 2023 Jan; 39(1):71-76.Yanamandra U, Yadav N, … Das S
  • Tyrosine kinase inhibitors (TKIs) have improved outcomes of chronic myeloid leukemia (CML). However, 20-30% of patients require second-line TKIs following suboptimal response. The cost and adverse events limit their use in resource-constraint settings. We conducted a pilot study to ascertain the benefit of adding pioglitazone to TKIs with suboptimal response in real-world resource-constraint sett…
  • Impact of PPAR-gamma activation on the durability of biological heart valve prostheses in hypercholesterolaemic rats. [Journal Article]
    Eur J Cardiothorac Surg. 2022 Dec 02; 63(1)Assmann AK, Winnicki V, … Akhyari P
  • CONCLUSIONS: Systemic peroxisome proliferator-activated receptor gamma activation decreases intima hyperplasia and subsequent intima calcification of cryopreserved allografts in obese, hypercholesterolaemic recipients. Additionally, it seems to inhibit functional impairment of the implanted aortic valve. Further preclinical studies are required to determine the long-term impact of peroxisome proliferator-activated receptor gamma agonists on graft durability.
  • Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. [Review]
    Cochrane Database Syst Rev. 2023 01 10; 1:CD010693.Liu J, Wang LN
  • CONCLUSIONS: Peroxisome proliferator-activated receptor gamma agonists probably reduce recurrent stroke and total events of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, and may improve insulin sensitivity and the stabilisation of carotid plaques. Their effects on adverse events are uncertain. Our conclusions should be interpreted with caution considering the small number and the quality of the included studies. Further well-designed, double-blind RCTs with large samples are required to assess the efficacy and safety of PPAR-γ agonists in the secondary prevention of stroke and related vascular events in people with stroke or TIA.
  • Diabetes and Stroke: What Are the Connections? [Review]
    J Stroke. 2023 Jan 03 [Online ahead of print]Mosenzon O, Cheng AY, … Sacco S
  • Stroke is a major cause of death and long-term disability worldwide. Diabetes is associated with an increased risk of cardiovascular complications, including stroke. People with diabetes have a 1.5-2 times higher risk of stroke compared with people without diabetes, with risk increasing with diabetes duration. These risks may also differ according to sex, with a greater risk observed among women …
  • NAFLD and type 2 diabetes: A practical guide for the joint management. [Review]
    Gastroenterol Hepatol. 2022 Dec 27 [Online ahead of print]Genua I, Iruzubieta P, … Crespo J
  • Non-alcoholic fatty liver disease (NAFLD) is becoming a major cause of liver disease-related morbidity, as well as mortality. Importantly, NAFLD is considered a mediator of systemic diseases including cardiovascular disease. Its prevalence is expected to increase, mainly due to its close association with obesity and type 2 diabetes mellitus (T2D). In addition, T2D and NAFLD share common pathophys…
  • The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes. [Review]
    Int J Mol Sci. 2022 Dec 12; 23(24)Wronka M, Krzemińska J, … Franczyk B
  • Diabetes is considered a new pandemic of the modern world, and the number of sufferers is steadily increasing. Sustained hyperglycemia promotes the production of free radicals and leads to persistent, low-grade inflammation. Oxidative stress causes mitochondrial destruction, which along with activation of the hexosamine pathway, nuclear factor-κB (Nf-κb), p38 mitogen-activated protein kinase (p38…
  • A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis. [Review]
    Int J Environ Res Public Health. 2022 12 09; 19(24)Turosz N, Chęcińska K, … Chlubek D
  • Thiazolidinediones (TZDs) are a group of diabetes medications currently being investigated for anti-arthritis effectiveness, one of which is pioglitazone. The purpose of this scoping review is to evaluate the potential use of pioglitazone in the treatment of temporomandibular joint (TMJ) arthritis. The criteria of eligibility were studies with the diagnosis of arthritis and pioglitazone treatment…
New Search Next